Oculis Holding AG (OCS) Debt Ratio (2021 - 2024)
Quarterly Debt Ratio changed N/A to 0.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was 0.0 through Mar 2024, changed N/A year-over-year, with the annual reading at 0.0 for FY2023, 99.9% down from the prior year.
Oculis Holding AG's Debt Ratio history spans 4 years, with the latest figure at 0.0 for Q1 2024.
- Debt Ratio came in at 0.0 for Q1 2024, up from 0.0 in the prior quarter.
- In the past five years, Debt Ratio ranged from a high of 3.3 in Q4 2022 to a low of 0.0 in Q3 2023.
- The 4-year median for Debt Ratio is 0.0 (2024), against an average of 1.05.
- Year-over-year, Debt Ratio soared 68.96% in 2022 and then plummeted 99.9% in 2023.
- Oculis Holding AG's Debt Ratio stood at 1.96 in 2021, then soared by 68.96% to 3.3 in 2022, then tumbled by 99.9% to 0.0 in 2023, then rose by 15.84% to 0.0 in 2024.
- Per Business Quant, the three most recent readings for OCS's Debt Ratio are 0.0 (Q1 2024), 0.0 (Q4 2023), and 0.0 (Q3 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 0.18 |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 1.41 |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 0.05 |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.00 |
| Dec 31, 2022 | 3.30 |
| Dec 31, 2021 | 1.96 |